1. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System

   • Bharati Bhardwaja
   • Shilpa Klocke
   • Kari L. Olson

   Leading Article 24 November 2021 Pages: 1 - 11

   

2. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy

   • Shambavi Richard
   • Sundar Jagannath

   Review Article 03 February 2022 Pages: 13 - 25

   

3. Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review

   • Rosanne W. Meijboom
   • Helga Gardarsdottir
   • Thijs J. Giezen

   Systematic Review Open access 06 December 2021 Pages: 27 - 39

   

4. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin

   • Andreas Volk
   • Caroline Covini-Souris
   • Torben Schmidt

   Original Research Article Open access 29 November 2021 Pages: 41 - 53

   

5. Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

   • Rubi K. Li
   • Eriko Tokunaga
   • Oleg Lipatov

   Original Research Article Open access 08 February 2022 Pages: 55 - 69

   

6. Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians

   • Jingyan Yang
   • Kelly Blinzler
   • Ahmed Shelbaya

   Original Research Article Open access 25 November 2021 Pages: 71 - 83

7. A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn’s Disease

   • Pavine L. C. Lefevre
   • Parambir S. Dulai
   • Niels Vande Casteele

   Original Research Article 24 December 2021 Pages: 85 - 93